HUTCHMED (China) (HUTCHMED (China)) EBIT : $59.1 Mil (TTM As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) EBIT?

HUTCHMED (China)'s earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was $-52.6 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $59.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. HUTCHMED (China)'s annualized ROC % for the quarter that ended in Dec. 2023 was -37.74%. HUTCHMED (China)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -104.54%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. HUTCHMED (China)'s Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 2.43%.

HUTCHMED (China) EBIT Historical Data

The historical data trend for HUTCHMED (China)'s EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) EBIT Chart

HUTCHMED (China) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

-140.08

-188.95

-215.15

-409.77

59.07

HUTCHMED (China) Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															-71.41	-196.75	-213.02	111.65	-52.59

Competitive Comparison of HUTCHMED (China)'s EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, HUTCHMED (China)'s EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HUTCHMED (China)'s EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HUTCHMED (China)'s EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where HUTCHMED (China)'s EV-to-EBIT falls into.

HUTCHMED (China) EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $59.1 Mil.

HUTCHMED (China) (NAS:HCM) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

HUTCHMED (China)'s annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	-186.558 * ( 1 - -2.26% )	/	( (480.127	+	530.956)	/ 2 )
=	-190.7742108	/	505.5415
=	-37.74 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1297.497	-	67.748	-	( 856.168	-	max(0, 340.863	-	1090.485	+	856.168	))
=	480.127

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1279.773	-	55.005	-	( 886.336	-	max(0, 403.027	-	1096.839	+	886.336	))
=	530.956

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

HUTCHMED (China)'s annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-105.174	/	( ( (96.829 + max(-137.481, 0))	+	(104.392 + max(-192.35, 0)) )	/	2 )
=	-105.174	/	( ( 96.829	+	104.392 )	/	2 )
=	-105.174	/	100.6105
=	-104.54 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(129.203	+	53.875	+	20.304)	-	(67.748	+	0	+	273.115)
=	-137.481

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(114.998	+	50.258	+	10.339)	-	(55.005	+	0	+	312.94)
=	-192.35

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

HUTCHMED (China)'s Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	59.067	/	2432.923
	=	2.43 %

HUTCHMED (China) EBIT Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

HUTCHMED (China) (HUTCHMED (China)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

00013:Hong Kong HCM.GB:UK HCM:UK H7T2:Germany

Address

2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG

Website

https://www.hutch-med.com

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.